28.93
0.59 (2.08%)
| 前收盘价格 | 28.34 |
| 收盘价格 | 28.66 |
| 成交量 | 1,799,472 |
| 平均成交量 (3个月) | 2,114,714 |
| 市值 | 2,935,670,272 |
| 价格/销量 (P/S) | 41.70 |
| 股市价格/股市净资产 (P/B) | 2.60 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业利益率 (TTM) | -1,596.87% |
| 稀释每股收益 (EPS TTM) | -4.61 |
| 季度收入增长率 (YOY) | 0.80% |
| 总债务/股东权益 (D/E MRQ) | 14.08% |
| 流动比率 (MRQ) | 8.81 |
| 营业现金流 (OCF TTM) | -351.38 M |
| 杠杆自由现金流 (LFCF TTM) | -185.90 M |
| 资产报酬率 (ROA TTM) | -19.05% |
| 股东权益报酬率 (ROE TTM) | -38.04% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Beam Therapeutics Inc. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | -4.0 |
| 价格波动 | -4.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -1.40 |
|
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 1.22% |
| 机构持股比例 | 98.07% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Mwg Management Ltd. | 30 Sep 2025 | 2,266,934 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 41.00 (Bernstein, 41.72%) | 购买 |
| 中 | 35.00 (20.98%) | |
| 低 | 28.00 (UBS, -3.22%) | 保留 |
| 平均值 | 34.67 (19.84%) | |
| 总计 | 2 购买, 1 保留 | |
| 平均价格@调整类型 | 27.89 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Bernstein | 21 Jan 2026 | 41.00 (41.72%) | 购买 | 31.12 |
| UBS | 07 Jan 2026 | 28.00 (-3.21%) | 保留 | 28.93 |
| Evercore ISI Group | 24 Nov 2025 | 35.00 (20.98%) | 购买 | 23.62 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| EVANS JOHN M. | - | 28.46 | -50,000 | -1,422,750 |
| 累积净数量 | -50,000 | |||
| 累积净值 ($) | -1,422,750 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 28.46 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| EVANS JOHN M. | 职员 | 30 Jan 2026 | 自动卖出 (-) | 25,000 | 27.62 | 690,500 |
| EVANS JOHN M. | 职员 | 30 Jan 2026 | 执行期权 | 25,000 | - | - |
| EVANS JOHN M. | 职员 | 29 Jan 2026 | 自动卖出 (-) | 25,000 | 29.29 | 732,250 |
| EVANS JOHN M. | 职员 | 29 Jan 2026 | 执行期权 | 25,000 | - | - |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合